Targeting death-inducing receptors in cancer therapy.

摘要: Deregulated cell death pathways may lead to the development of cancer, and induction tumor apoptosis is basis many cancer therapies. Knowledge accumulated concerning molecular mechanisms apoptotic has aided new therapeutic strategies treat cancer. Signals through receptors necrosis factor (TNF) superfamily have been well elucidated, are now one most attractive targets in In particular, DR5 DR4, TNF-related apoptosis-inducing ligand (TRAIL or Apo2L), interesting antibody-based therapy, since TRAIL also bind decoy that prevent TRAIL-mediated apoptosis, whereas itself selectively induces cells. Here, we review potential utility agonistic antibodies against DR4 discuss possible extension this single-antibody-based strategy when combined with additional modalities either synergizes cause enhanced further engage cellular immune response. Rational design therapies combining activation tumor-specific adaptive immunity enables promotion distinct steps antitumor response, thereby enhancing lymphocytes can eradicate TRAIL/DR5-resistant mutating, large established heterogeneous tumors a manner does not require definition individual antigens.